Resuscitation of traumatic hemorrhagic shock patients with hypertonic saline - without dextran - inhibits neutrophil and endothelial cell activation

Details

• Alternative Title:
  Shock
• Personal Author:
  Junger, Wolfgang G. ; Rhind, Shawn G. ; Rizoli, Sandro B. ; Cuschieri, Joseph ; Shiu, Maria Y. ; Baker, Andrew J. ; Li, Linglin ; Shek, Pang N. ; Hoyt, David B. ; Bulger, Eileen M.
• Description:
  Background
  
  Post-traumatic inflammation and excessive neutrophil activation cause multiple organ dysfunction syndrome (MODS), a major cause of death among hemorrhagic shock patients. Traditional resuscitation strategies may exacerbate inflammation and thus novel fluid treatments are needed to reduce these post-traumatic complications. Hypertonic resuscitation fluids inhibit inflammation and reduce MODS in animal models. Here we studied the anti-inflammatory efficacy of hypertonic fluids in a controlled clinical trial.
  
  Methods
  
  Trauma patients in hypovolemic shock were resuscitated in a pre-hospital setting with 250 ml of either 7.5% hypertonic saline (HS; n=9), 7.5% hypertonic saline + 6% dextran-70 (HSD; n=8), or 0.9% normal saline (NS; n=17). Blood samples were collected on hospital admission and 12 and 24 h post-resuscitation. Multi-color flow cytometry was used to quantify neutrophil expression of cell-surface activation/adhesion (CD11b, CD62L, CD64) and degranulation (CD63, CD66b, CD35) markers as well as oxidative burst activity. Circulating concentrations of soluble intercellular adhesion molecule (sICAM)-1, vascular cell adhesion molecule (sVCAM)-1, P-, E-selectins, myeloperoxidase (MPO), and matrix metallopeptidase (MMP)-9 were assessed with immunoassays.
  
  Results
  
  MODS, leukocytosis, and mortality were lower in the HS and HSD groups than in the NS group. However, these differences were not statistically significant. HS prevented priming and activation and neutrophil oxidative burst and CD11b and CD66b expression. HS also reduced circulating markers of neutrophil degranulation (MPO and MMP-9) and endothelial cell activation (sICAM-1, cVCAM-1, sE-selectin, and sP-selectin). HSD was less capable than HS of suppressing the upregulation of most of these activation markers.
  
  Conclusions
  
  This study demonstrates that initial resuscitation with HS but neither NS nor HSD can attenuate post-traumatic neutrophil and endothelial cell activation in hemorrhagic shock patients. These data suggest that hypertonic resuscitation without dextran may inhibit post-traumatic inflammation. However, despite this effect, neither HS nor HSD reduced MODS in trauma patients with hemorrhagic shock.
  
  
• Subjects:
  Adolescent Adult Aged Animals Disease Models, Animal Endothelial Cells Female Humans Hypovolemia Male Middle Aged Multiple Organ Failure Neutrophil Activation Neutrophils Resuscitation Saline Solution, Hypertonic Shock, Hemorrhagic Wounds And Injuries

  More +
• Source:
  Shock. 38(4):341-350.
• Pubmed ID:
  22777113
• Pubmed Central ID:
  PMC3455119
• Document Type:
  Journal Article
• Funding:
  5U01HL077863/HL/NHLBI NIH HHS/United States ; AI-072287/AI/NIAID NIH HHS/United States ; AI-080582/AI/NIAID NIH HHS/United States ; GM-51477/GM/NIGMS NIH HHS/United States ; GM-60475/GM/NIGMS NIH HHS/United States ; HL077865/HL/NHLBI NIH HHS/United States ; HL077866/HL/NHLBI NIH HHS/United States ; HL077867/HL/NHLBI NIH HHS/United States ; HL077871/HL/NHLBI NIH HHS/United States ; HL077872/HL/NHLBI NIH HHS/United States ; HL077873/HL/NHLBI NIH HHS/United States ; HL077881/HL/NHLBI NIH HHS/United States ; HL077885/HL/NHLBI NIH HHS/United States ; HL077887/HL/NHLBI NIH HHS/United States ; HL077908/HL/NHLBI NIH HHS/United States ; PR043034/PR/OCPHP CDC HHS/United States ; R01 AI072287/AI/NIAID NIH HHS/United States ; R01 AI080582/AI/NIAID NIH HHS/United States ; R01 GM051477/GM/NIGMS NIH HHS/United States ; R01 GM060475/GM/NIGMS NIH HHS/United States ; R01 GM076101/GM/NIGMS NIH HHS/United States ; R01 HL073233/HL/NHLBI NIH HHS/United States ; R29 GM051477/GM/NIGMS NIH HHS/United States ; Canadian Institutes of Health Research/Canada
• Volume:
  38
• Issue:
  4
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:1eb9f6161a5c16f5866297e93cdfc0bbdc932022b446433bc6749c7a0c5dc5c1
• Download URL:
  https://stacks.cdc.gov/view/cdc/33434/cdc_33434_DS1.pdf
• File Type:
  [PDF - 1.68 MB ]